Mallinckrodt Stock Price, News & Analysis (NYSE:MNK)

$23.86 -0.20 (-0.83 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$24.06
Today's Range$23.84 - $24.62
52-Week Range$19.00 - $55.32
Volume2.92 million shs
Average Volume2.59 million shs
Market Capitalization$2.20 billion
P/E Ratio3.12
Dividend YieldN/A
Beta1.3

About Mallinckrodt (NYSE:MNK)

Mallinckrodt logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio1.08%
Current Ratio1.38%
Quick Ratio1.05%

Price-To-Earnings

Trailing P/E Ratio3.12
Forward P/E Ratio3.31
P/E Growth0.42

Sales & Book Value

Annual Sales$829.90 million
Price / Sales2.73
Cash Flow$0.26 per share
Price / Cash91.84
Book Value$47.57 per share
Price / Book0.50

Profitability

Trailing EPS$3.70
Net Income$-153,200,000.00
Net Margins11.43%
Return on Equity14.79%
Return on Assets5.07%

Miscellaneous

Employees4,500
Outstanding Shares95,000,000

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its Board of Directors has authorized a share repurchase plan on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 18.5% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) posted its earnings results on Tuesday, November, 7th. The company reported $1.97 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.17. The business had revenue of $793.90 million for the quarter, compared to analyst estimates of $808.93 million. Mallinckrodt had a net margin of 11.43% and a return on equity of 14.79%. Mallinckrodt's revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.04 earnings per share. View Mallinckrodt's Earnings History.

When will Mallinckrodt make its next earnings announcement?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Mallinckrodt.

Where is Mallinckrodt's stock going? Where will Mallinckrodt's stock price be in 2017?

18 equities research analysts have issued 12 month price targets for Mallinckrodt's stock. Their forecasts range from $23.00 to $98.00. On average, they anticipate Mallinckrodt's stock price to reach $49.31 in the next year. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio. The company sold its Nuclear Imaging business and Intrathecal Therapy business. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments and we expect Acthar sales to drive growth. However, sales of Therakos is expected to decline. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax." (11/6/2017)
  • 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
  • 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)

Are investors shorting Mallinckrodt?

Mallinckrodt saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 24,753,346 shares, an increase of 11.0% from the November 15th total of 22,292,861 shares. Based on an average daily trading volume, of 3,783,377 shares, the days-to-cover ratio is presently 6.5 days. Currently, 26.3% of the company's shares are sold short.

Who are some of Mallinckrodt's key competitors?

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:

  • Melvin D. Booth Ph.D. CPA, Independent Chairman of the Board (Age 71)
  • Mark C. Trudeau, President, Chief Executive Officer, Director (Age 55)
  • Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President (Age 46)
  • Ian J. Watkins, Chief Human Resource Officer (Age 54)
  • Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies (Age 56)
  • Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer (Age 51)
  • Steven Romano, Executive Vice President and Chief Scientific Officer (Age 57)
  • Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics (Age 47)
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases (Age 53)
  • Raymond J. Furey, Chief Compliance Officer (Age 48)

Who owns Mallinckrodt stock?

Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (2.66%), Ameriprise Financial Inc. (2.00%), Alyeska Investment Group L.P. (1.62%), Orbimed Advisors LLC (1.55%), Prudential Financial Inc. (1.39%) and Bank of New York Mellon Corp (1.18%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Who sold Mallinckrodt stock? Who is selling Mallinckrodt stock?

Mallinckrodt's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., SG Americas Securities LLC, Teacher Retirement System of Texas, Meyer Handelman Co., APG Asset Management N.V., AMP Capital Investors Ltd, PGGM Investments and Rhumbline Advisers. View Insider Buying and Selling for Mallinckrodt.

Who bought Mallinckrodt stock? Who is buying Mallinckrodt stock?

Mallinckrodt's stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Alyeska Investment Group L.P., Bank of New York Mellon Corp, Dimensional Fund Advisors LP, First Manhattan Co., Broadwood Capital Inc., Principal Financial Group Inc. and Orbimed Advisors LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy Mallinckrodt stock?

Shares of Mallinckrodt can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of Mallinckrodt stock can currently be purchased for approximately $23.86.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $2.20 billion and generates $829.90 million in revenue each year. The company earns $-153,200,000.00 in net income (profit) each year or $3.70 on an earnings per share basis. Mallinckrodt employs 4,500 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]


MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  585 (Vote Outperform)
Underperform Votes:  326 (Vote Underperform)
Total Votes:  911
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mallinckrodt (NYSE:MNK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.442.562.792.84
Ratings Breakdown: 0 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.31$49.31$69.34$78.50
Price Target Upside: 113.08% upside151.11% upside94.56% upside87.17% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017BarclaysSet Price TargetHold$23.00HighView Rating Details
11/22/2017OppenheimerReiterated RatingOutperform -> Market PerformN/AView Rating Details
11/14/2017Canaccord GenuitySet Price TargetHold$24.00N/AView Rating Details
11/8/2017Stifel NicolausLower Price TargetBuy$70.00 -> $50.00N/AView Rating Details
11/8/2017Morgan StanleyLower Price TargetEqual Weight$40.00 -> $27.00N/AView Rating Details
11/8/2017BMO Capital MarketsLower Price TargetOutperform$38.00N/AView Rating Details
11/8/2017Goldman Sachs GroupDowngradeBuy -> Neutral$55.00N/AView Rating Details
11/8/2017Jefferies GroupInitiated CoverageMarket Perform -> Buy$60.00 -> $30.00N/AView Rating Details
11/8/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
11/7/2017CitigroupDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/7/2017Deutsche BankDowngradeBuy -> Hold$44.00 -> $28.00N/AView Rating Details
11/2/2017Cantor FitzgeraldReiterated RatingBuy$52.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$67.00N/AView Rating Details
10/15/2017MizuhoReiterated RatingHold$40.00N/AView Rating Details
8/9/2017Raymond James FinancialLower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$1.97N/AView Earnings Details
11/7/2017Q3 2017$1.80$1.97$808.93 million$793.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Mallinckrodt (NYSE:MNK) Earnings Estimates

2017 EPS Consensus Estimate: $7.28
2018 EPS Consensus Estimate: $7.82
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.80
Q3 20173$1.81$1.89$1.86
Q4 20173$1.75$2.02$1.91
Q1 20183$1.44$1.82$1.60
Q2 20182$1.66$2.15$1.91
Q3 20182$2.07$2.10$2.09
Q4 20182$1.98$2.48$2.23
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mallinckrodt (NYSE:MNK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 97.40%
Insider Trades by Quarter for Mallinckrodt (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2017Dr Kneeland YoungbloodDirectorBuy4,560$21.94$100,046.40View SEC Filing  
11/13/2017Joann A ReedDirectorBuy1,000$21.50$21,500.00View SEC Filing  
11/13/2017Steven J. RomanoVPBuy2,000$21.96$43,920.00View SEC Filing  
11/10/2017Mark TrudeauCEOBuy5,000$22.28$111,400.00View SEC Filing  
11/9/2017David R CarlucciDirectorBuy10,000$21.83$218,300.00View SEC Filing  
11/9/2017Michael-Bryant HicksGeneral CounselBuy7,900$20.80$164,320.00View SEC Filing  
8/30/2017Meredith B. FischerInsiderBuy1,280$39.63$50,726.40View SEC Filing  
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.00View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.50View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mallinckrodt (NYSE MNK) News Headlines

Source:
DateHeadline
Mallinckrodt (MNK) Completes Acquisition of Ocera Therapeutics (OCRX)Mallinckrodt (MNK) Completes Acquisition of Ocera Therapeutics (OCRX)
www.streetinsider.com - December 11 at 5:15 PM
Mallinckrodt (MNK) Completes Acquisition of Ocera Therapeutics (OCRX) - StreetInsider.comMallinckrodt (MNK) Completes Acquisition of Ocera Therapeutics (OCRX) - StreetInsider.com
www.streetinsider.com - December 11 at 10:31 AM
Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic EncephalopathyMallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
finance.yahoo.com - December 11 at 10:31 AM
Mallinckrodt To Present At 36th Annual J.P. Morgan Healthcare ConferenceMallinckrodt To Present At 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 8 at 9:47 AM
Bear of the Day: Mallinckrodt PLC (MNK)Bear of the Day: Mallinckrodt PLC (MNK)
finance.yahoo.com - December 8 at 9:47 AM
Mallinckrodt is Now Oversold (MNK)Mallinckrodt is Now Oversold (MNK)
www.nasdaq.com - December 6 at 5:05 PM
Mallinckrodt PLC (MNK) Given Average Recommendation of "Hold" by BrokeragesMallinckrodt PLC (MNK) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 1 at 10:06 AM
Dr Kneeland Youngblood Acquires 4,560 Shares of Mallinckrodt PLC (MNK) StockDr Kneeland Youngblood Acquires 4,560 Shares of Mallinckrodt PLC (MNK) Stock
www.americanbankingnews.com - November 30 at 10:30 AM
Mallinckrodt PLC (MNK) Rating Lowered to Neutral at UBS AGMallinckrodt PLC (MNK) Rating Lowered to Neutral at UBS AG
www.americanbankingnews.com - November 26 at 6:50 AM
Mallinckrodt PLC (MNK) PT Set at $24.00 by Canaccord GenuityMallinckrodt PLC (MNK) PT Set at $24.00 by Canaccord Genuity
www.americanbankingnews.com - November 25 at 1:32 PM
Mallinckrodt PLC (MNK) & Novan (NOVN) Financial ReviewMallinckrodt PLC (MNK) & Novan (NOVN) Financial Review
www.americanbankingnews.com - November 25 at 1:22 AM
Mallinckrodt: We Know Its Sick…and Its Not Getting BetterMallinckrodt: We Know It's Sick…and It's Not Getting Better
finance.yahoo.com - November 23 at 5:18 PM
FY2017 Earnings Estimate for Mallinckrodt PLC (MNK) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Mallinckrodt PLC (MNK) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 23 at 7:58 AM
Mallinckrodt PLC (MNK) Earns Market Perform Rating from Oppenheimer Holdings, Inc.Mallinckrodt PLC (MNK) Earns Market Perform Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 22 at 10:50 AM
The Straw That Broke Mallinckrodts Back? - Seeking AlphaThe Straw That Broke Mallinckrodt's Back? - Seeking Alpha
seekingalpha.com - November 22 at 5:24 AM
Oppenheimer Downgrades Mallinckrodt plc (MNK) to Perform - StreetInsider.comOppenheimer Downgrades Mallinckrodt plc (MNK) to Perform - StreetInsider.com
www.streetinsider.com - November 22 at 5:24 AM
Mallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA Meeting - StreetInsider.comMallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA Meeting - StreetInsider.com
www.streetinsider.com - November 18 at 8:17 AM
Mallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA MeetingMallinckrodt (MNK) Presents Health Economic Data on OFIRMEV Injection at ASRA Meeting
www.streetinsider.com - November 18 at 12:46 AM
Mallinckrodt To Present At The BMO Prescriptions for Success Healthcare ConferenceMallinckrodt To Present At The BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - November 15 at 6:26 AM
Why Mallinckrodt Cratered - Mallinckrodt PLC (NYSE:MNK ... - Seeking AlphaWhy Mallinckrodt Cratered - Mallinckrodt PLC (NYSE:MNK ... - Seeking Alpha
seekingalpha.com - November 14 at 2:59 AM
Mallinckrodt Stock Lowered to Neutral at UBS Over Persisting ConcernsMallinckrodt Stock Lowered to 'Neutral' at UBS Over Persisting Concerns
finance.yahoo.com - November 14 at 2:59 AM
Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%Mallinckrodt Bull Turns Bear, Slashes Price Target By 66%
finance.yahoo.com - November 14 at 2:59 AM
Insider Buying: Mallinckrodt PLC (MNK) Director Acquires 1,000 Shares of StockInsider Buying: Mallinckrodt PLC (MNK) Director Acquires 1,000 Shares of Stock
www.americanbankingnews.com - November 13 at 7:52 PM
Mallinckrodt PLC (MNK) VP Purchases $43,920.00 in StockMallinckrodt PLC (MNK) VP Purchases $43,920.00 in Stock
www.americanbankingnews.com - November 13 at 6:54 PM
Mallinckrodt PLC (MNK) CEO Buys $111,400.00 in StockMallinckrodt PLC (MNK) CEO Buys $111,400.00 in Stock
www.americanbankingnews.com - November 13 at 6:26 PM
David R. Carlucci Acquires 10,000 Shares of Mallinckrodt PLC (MNK) StockDavid R. Carlucci Acquires 10,000 Shares of Mallinckrodt PLC (MNK) Stock
www.americanbankingnews.com - November 13 at 4:51 PM
Mallinckrodt PLC (MNK) General Counsel Michael-Bryant Hicks Purchases 7,900 SharesMallinckrodt PLC (MNK) General Counsel Michael-Bryant Hicks Purchases 7,900 Shares
www.americanbankingnews.com - November 13 at 4:50 PM
FY2017 EPS Estimates for Mallinckrodt PLC Decreased by Cantor Fitzgerald (MNK)FY2017 EPS Estimates for Mallinckrodt PLC Decreased by Cantor Fitzgerald (MNK)
www.americanbankingnews.com - November 13 at 2:58 AM
Mallinckrodt Plc: Strong price momentum but will it sustain?Mallinckrodt Plc: Strong price momentum but will it sustain?
finance.yahoo.com - November 12 at 7:43 AM
Stock Traders Purchase High Volume of Call Options on Mallinckrodt PLC (MNK)Stock Traders Purchase High Volume of Call Options on Mallinckrodt PLC (MNK)
www.americanbankingnews.com - November 11 at 2:42 AM
Jefferies Group Analysts Decrease Earnings Estimates for Mallinckrodt PLC (MNK)Jefferies Group Analysts Decrease Earnings Estimates for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - November 10 at 3:04 PM
FY2017 Earnings Forecast for Mallinckrodt PLC Issued By Jefferies Group (MNK)FY2017 Earnings Forecast for Mallinckrodt PLC Issued By Jefferies Group (MNK)
www.americanbankingnews.com - November 9 at 7:35 AM
Mallinckrodt plc (MNK) PT Lowered to $30 at JefferiesMallinckrodt plc (MNK) PT Lowered to $30 at Jefferies
www.streetinsider.com - November 9 at 1:50 AM
Mallinckrodt plc (MNK) PT Lowered to $24 at Canaccord Genuity - StreetInsider.comMallinckrodt plc (MNK) PT Lowered to $24 at Canaccord Genuity - StreetInsider.com
www.streetinsider.com - November 8 at 8:48 PM
Goldman Sachs Downgrades Mallinckrodt plc (MNK) to Neutral - StreetInsider.comGoldman Sachs Downgrades Mallinckrodt plc (MNK) to Neutral - StreetInsider.com
www.streetinsider.com - November 8 at 8:48 PM
ETFs with exposure to Mallinckrodt Plc : November 8, 2017ETFs with exposure to Mallinckrodt Plc : November 8, 2017
finance.yahoo.com - November 8 at 8:48 PM
Mallinckrodt Enters Oversold Territory (MNK) - NasdaqMallinckrodt Enters Oversold Territory (MNK) - Nasdaq
www.nasdaq.com - November 8 at 3:48 PM
Mallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray - StreetInsider.comMallinckrodt plc (MNK) PT Lowered to $40 at Piper Jaffray - StreetInsider.com
www.streetinsider.com - November 8 at 3:48 PM
Wells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform - StreetInsider.comWells Fargo Downgrades Mallinckrodt plc (MNK) to Market Perform - StreetInsider.com
www.streetinsider.com - November 8 at 3:48 PM
Mallinckrodt shares drop 8.6% after Q3 profit, revenue missesMallinckrodt shares drop 8.6% after Q3 profit, revenue misses
finance.yahoo.com - November 8 at 3:48 PM
Pharma company Mallinckrodt on pace for worst day ever, s...Pharma company Mallinckrodt on pace for worst day ever, s...
finance.yahoo.com - November 8 at 3:48 PM
Edited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of MNK earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 3:47 PM
Charting the Market: Mallinckrodt Tumbles 35%Charting the Market: Mallinckrodt Tumbles 35%
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt Nosedives After Sales Lag, Though Earnings Top ViewsMallinckrodt Nosedives After Sales Lag, Though Earnings Top Views
finance.yahoo.com - November 8 at 3:47 PM
[$$] Why Mallinckrodt’s Woes Matter to All Drug Makers[$$] Why Mallinckrodt’s Woes Matter to All Drug Makers
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt shares drop after Goldman downgradeMallinckrodt shares drop after Goldman downgrade
finance.yahoo.com - November 8 at 3:47 PM
Company News For Nov 8, 2017Company News For Nov 8, 2017
finance.yahoo.com - November 8 at 3:47 PM
Heres Why Mallinckrodt Stock Plummeted to an All-Time LowHere's Why Mallinckrodt Stock Plummeted to an All-Time Low
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt: Look Out Below!Mallinckrodt: Look Out Below!
finance.yahoo.com - November 8 at 3:47 PM
Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3Mallinckrodt (MNK) Earnings, Sales Decline Y/Y in Q3
finance.yahoo.com - November 8 at 3:47 PM

SEC Filings

Mallinckrodt (NYSE:MNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mallinckrodt (NYSE MNK) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.